Vaccine Adjuvants Market

Vaccine Adjuvants Market Outlook (2023 to 2033)

Newly-released vaccine adjuvants market analysis report by Fact.MR reveals that global sales of the Vaccine Adjuvants in 2022 were held at US$ 1.9 Billion. With 12.3% projected growth from 2023 to 2033, the market is expected to reach a valuation of US$ 6.8 Billion by the end of the forecast period.

Adjuvant emulsions are expected to be the significant revenue-generating type in the market, projected to grow at a CAGR of over 12.1% from 2023 to 2033.

Attributes	Details
Global Vaccine Adjuvants Market Size (2022)	US$ 1.9 Billion
Global Vaccine Adjuvants Market Size (2033)	US$ 6.8 Billion
Global Vaccine Adjuvants Market CAGR (2023 to 2033)	12.3%
U.S. Vaccine Adjuvants Market CAGR (2023 to 2033)	12%
Key Companies Covered	GSK Plc Dynavax Technologies Novavax Agenus Inc. Croda International Plc Seppic Phibro Animal Health Corporation Spi Pharma CSL Limited Merck KGAA OZ Biosciences Invivogen Allergy Therapeutics Vertellus Eubiologics Co. Ltd.

Revenue of Vaccine Adjuvants Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per the research of the vaccine adjuvants market by Fact.MR - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 14.6% CAGR. With an absolute dollar opportunity of US$ 4.7 Billion, the market is projected to reach a valuation of US$ 6.8 Billion by 2033.

What Key Drivers are Influencing the Market Expansion?

The key drivers influencing vaccine adjuvants market expansion include rising demand for vaccines, advancement in biotechnology, a growing number of people with infectious diseases, government funding, and increasing investment in R&D.

Vaccine adjuvants are substances that are added to vaccines to boost the immune response and increase the effectiveness of the vaccine. This is used for the preparation of human vaccines and veterinary vaccines. The human vaccine includes diabetes, cancer, Tuberculosis, Influenza, COVID-19, and BCG vaccines. Vaccine adjuvants are used for the prevention and treatment of various types of infectious diseases.

In 2019, According to International Diabetes Federation, people between the age group 20 to 79 suffered from diabetes, and the number accounted to be 463 million worldwide. Diabetic vaccines are playing a significant role in the prevention and treatment of diabetes. So the demand for a more effective vaccine has increased. Vaccines that contain adjuvants are more long-lasting, immune, and more effective. As a result, there is a growing demand for vaccine adjuvants for prevention and treatment.

In 2021, Adjuvant Capital, a life science investment firm raised US$ 300 million for companies that are producing vaccines and adjuvants for infectious diseases. The investment in vaccine adjuvants has increased in the last few years which is expected to escalate the market growth.

Several companies formed collaborations and partnerships for the development of new vaccines and vaccine adjuvants. Advax a novel adjuvant that is used in the COVID-19 vaccine was developed by Vaxine Pty Ltd with the partnership firm Medytox. Due to these factors, the demand for vaccine adjuvants is expected to increase.

Region-Wise Analysis

Which Region is Projected to Offer Significant Growth in the Market?

North America is a prominent shareholder in the market with a market size of US$ 780 million in 2022 and is estimated to reach US$ 879 million in 2023. It is projected that the region will have a market worth US$ 2.7 Billion by 2033.

In 2020, liver cancer was the third leading cause of death worldwide. Over 830 thousand people were diagnosed and 41 thousand people died due to liver cancer in the United States. The hepatitis-B vaccine is used for the prevention and treatment of liver cancer. Due to the increasing demand for vaccines and vaccine adjuvants, the vaccine adjuvant market is expected to rise.

Country-Wise Analysis

United States Vaccine Adjuvants Market Analysis :

The market in the United States is expected to grow to be worth US$ 2.4 Billion by 2033, with an absolute dollar growth of US$ 1.6 Billion from 2023 to 2033. The market in the United States has grown at a CAGR of 14.2% from 2018 to 2022 and is expected to grow at a CAGR of 12% from the year 2023 to 2033.

United Kingdom Vaccine Adjuvants Market Analysis :

The market in the United Kingdom is expected to grow to be worth US$ 261.2 million by 2033, with an absolute dollar growth of US$ 171.6 million. The market in the United Kingdom has grown at a CAGR of 12.9% from 2018 to 2022 and is expected to grow at a CAGR of 11.3% from 2023 to 2033.

In 2019, around 387 thousand cases were diagnosed with cancer, and around 166 thousand deaths were reported in the United Kingdom. In cancer vaccines, adjuvants are used to stimulate the immune system to recognize and attack cancer cells. As a result, there is a growing demand for vaccine adjuvants for the prevention and treatment of cancer. Thus, it is expected to propel the market in the upcoming years.

China Vaccine Adjuvants Market Analysis :

In China, the market is expected to grow to be worth US$ 534.6 million with an absolute dollar growth of US$ 356.7 million. The market in China has grown at a CAGR of 13.6% from 2018 to 2022 and is expected to grow at a CAGR of 11.6% from 2023 to 2033.

According to WHO, China was significantly affected by the COVID-19 virus, over 9.8 million cases were diagnosed and 119 thousand people died in 2020. The vaccines COVISHIELD and COVAXIN are used for the prevention and treatment of Covid-19. Vaccine Adjuvants such as AS03, MF59, and CpG 1018 have been used in COVID-19 vaccines to enhance their efficacy. This influences market growth.

Japan Vaccine Adjuvants Market Analysis :

In Japan, the market is expected to grow to be worth US$ 437 million with an absolute dollar growth of US$ 279 Million. The market in Japan has grown at a CAGR of 12.2% from 2018 to 2022 and is expected to grow at a CAGR of 10.7% from 2023 to 2033.

In 2018, the number of cancer cases diagnosed in Japan was around 883 thousand while around 409 thousand deaths were reported. The most common cancer in Japan is cervical cancer. Human papillomavirus (HPV) vaccine helps to prevent cervical cancer and other diseases caused by HPV Virus. The adjuvants used in HPV vaccines are aluminum salts, AS04, CpG oligonucleotides, and polysorbate 80. In 2018, the total sales of the Human papillomavirus (HPV) vaccine in Japan were over USD 127 million. The surging demand for vaccines is expected to increase the demand for vaccine adjuvants.

India Vaccine Adjuvants Market Analysis :

The market in India is expected to grow to be worth US$ 267.3 million by 2033, with an absolute dollar growth of US$ 167.6 million. The market in the country has grown at a CAGR of 11.6% from 2018 to 2022 and is expected to grow at a CAGR of 10.4% from 2023 to 2033.

According to research, in 2018, the number of new cases of cervical cancer was about 527 thousand. It is the most common type of cancer in women worldwide and has more death ratio than other cancer. Human papillomavirus (HPV) vaccination is an effective treatment for cervical cancer. These factors are expected to trigger the demand for vaccine adjuvants in the upcoming years.

Category-Wise Insights

Which Product in the Market is Projected to Witness the Significant Growth?

Demand for adjuvant emulsions is projected to witness significant growth with a CAGR of 14.4% from 2018 to 2022 and is expected to grow at a CAGR of 12.1% from 2023 to 2033.

Adjuvant emulsions are a type of vaccine adjuvant, which are additives added to vaccinations to improve their capacity to stimulate an immune response. Oil and water are combined to form adjuvant emulsions, which promote the distribution of antigens to immune cells and boost the body's defense system, against the vaccine. MF59 is a widely used adjuvant emulsion, which is used for various vaccines such as flu vaccines.

Competitive Analysis

Key players in the market are GSK Plc, Dynavax Technologies, Novavax, Agenus Inc., Croda International Plc, Seppic, Phibro Animal Health Corporation, Spi Pharma, CSL Limited, Merck KGAA, OZ Biosciences, Invivogen, Allergy Therapeutics, Vertellus, and Eubiologics Co. Ltd.

A few of the recent developments in the market are :

• In Oct 2022, GSK acquired Affinivax, a Cambridge-based clinical-stage Biopharmaceutical Company that develops a novel class of vaccines and the most advanced next generation Pneumococcal vaccine.
• In April 2020, Dynavax partnered with Valneva, a French vaccine company, to develop a vaccine for COVID-19. The vaccine uses Dynavax's adjuvant technology.
• In February 2021, Merck extended its collaborative partnership with BioNTech to accelerate the essential lipid supply and amount of its delivery.

Segmentation of the Vaccine Adjuvants Market

• By Product :

  • Adjuvant Emulsions
  • Pathogen Components
  • Saponin-based Adjuvants
  • Particulate Adjuvants
  • Other Products

• By Route of Administration :

  • Intramuscular
  • Subcutaneous
  • Other Route of Administration

• By Disease Type :

  • Infectious Diseases
  • Cancer
  • Others

• By Application :

  • Research Application
  • Commercial Application

• By End User :

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

• By Region :

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa